Clémence Canivet's research while affiliated with Hôpital Universitaire Necker and other places
What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
Publications (2)
Background: The incidence of ventilator-associated pneumonia caused by Stenotrophomonas maltophilia (SM-VAP) is on the rise. This pathology is associated with increased morbidity and mortality in intensive care unit (ICU), notably due to intrinsic resistance and ineffective probabilistic antibiotic therapy. Our study aimed to determine the risk fac...
Background
Ventilator-associated pneumonia (VAP) caused by Stenotrophomonas maltophilia is poorly described in the literature. However, it has been shown to be associated with increased morbidity and mortality. Probabilistic antibiotic therapy against S. maltophilia is often ineffective as this pathogen is resistant to many antibiotics. There is no...
Citations
... It causes HAP in critically ill patients in the ICU due to its ability of biofilm formation and site adhesion in respiratory instruments and its intrinsic and acquired resistance to various antibiotics makes treatment difficult [130,131]. In recent studies, the incidence of VAP due to S. maltophilia was 0.27 to 0.93% [131][132][133]. It causes severe hemorrhagic pneumonia with a reported mortality rate of 100% [134]. ...
... At one end of the spectrum, patients who clearly manifest signs of infection with swinging fever, leucocytosis, and radiological signs of VAP should probably be started or continued with targeted antimicrobial therapy for the MDRO. This is even more important for patients with minimal physiological reserve and that have high risk of death, as delay in VAP treatment may be fatal [22,84,85]. At the other end of the spectrum, patients who have grown an MDRO in a respiratory sample taken for surveillance despite clinical improvement and do not exhibit signs of infection can likely be safely observed expectantly, as the MDRO is likely a colonizing organism. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/370067599577088-1465242399724_Q64/Guillaume-Miltgen.jpg)
